BioTherapeutics | 1800 Kraft Dr., Suite 200, Blacksburg, VA, 24060

The next frontier in precision medicine and health innovation for preventing and treating inflammation and metabolic disease.

BioTherapeutics Awarded New NIH Grant To Develop Medical Foods for Glycemic Control
BLACKSBURG, VA., Sept. 1, 2016 – BioTherapeutics, Inc. (BTI)—a biotech company that develops nutritionals for digestive health, immune health, and glycemic control—announced today...
News / September 01 2016
Pervida Brand Launches Media Campaign to Support Crowdfunding
BLACKSBURG, VA: Aug 19, 2016—Today, Blacksburg-based nutritional brand Pervida™ launched a media campaign in support of crowdfunding efforts. With articles in Roanoke Times and...
News / August 21 2016
Dr. William Sandborn Joins SAB
BLACKSBURG, VA: July 18, 2016—William J. Sandborn, MD—Chief, Division of Gastroenterology at University of California San Diego School of Medicine—has recently joined the...
News / July 19 2016

Our Purpose

Biotherapeutics Inc. (BTI) is a science-based biotechnology company that integrates Nutritionals, Therapeutics and IT to advance interventions for preventing and treating autoimmune and metabolic diseases.

See more about us
Precision Medicine and Health at BioTherapeutics
BLACKSBURG, VA: June 24, 2016 – Diabetes. Inflammatory Bowel Disease (IBD). Clostridium difficile-associated disease. These and a host of other diseases and syndromes have become...
News / June 24 2016
PERVIDA™—A Brand For a Healthy Lifestyle
BLACKSBURG, VA: June 11, 2016—What if you could drink your way to health? What if vending machines stocked with fortified waters could help maintain healthy blood sugar levels,...
News / June 11 2016
Abscisic acid: The Missing Hormone for Blood-Sugar Control Presented at ADA
NEW ORLEANS, LA: June 10, 2016— Diabetes affects nearly 30 million children and adults in the United States. More than 230,000 Americans die each year from complications of the...
News / June 10 2016
Toxicology Experiments Demonstrate that BT-11 has a Benign Safety Profile
BLACKSBURG, VA: May 31, 2016 – BTI Pharmaceuticals’ program lead for inflammatory bowel disease (IBD)—BT-11—has demonstrated an outstanding therapeutic efficacy in 3 validated mouse...
News / May 31 2016
BioTherapeutics Expands Scientific Advisory Board
BLACKSBURG, VA: May 28, 2016—Jean-Frederic Colombel, MD, an internationally renowned clinician and researcher in inflammatory bowel disease (IBD) and gastroenterology, has been appointed...
News / May 29 2016

Now Hiring

Interested in becoming a part of the BTI team? Take a look at our job openings

View all positions
BioTherapeutics Presents BT-11: A New First-in-Class Crohn’s Disease Therapeutic at DDW
SAN DIEGO, CA: May 23, 2016—Inflammatory bowel disease (IBD) and its two main clinical manifestations—ulcerative colitis (UC) and Crohn’s disease (CD)—afflict over 1.4 million...
News / May 23 2016
BioTherapeutics Presents a New First-in-class Therapeutic for Crohn’s disease at the VirginiaBrainRx Symposium
RICHMOND, VA: May 23, 2016 – BioTherapeutics (BTI) was invited to speak at VirginiaBrainRx about their clinical lead for inflammatory bowel disease (IBD), a debilitating autoimmune...
News / May 23 2016
Computing the Gut
BLACKSBURG, VA: May 1, 2016 – C. difficile is a spore-forming anaerobic bacterium associated with infections following the use of broad-spectrum antibiotics. The resultant disease is...
News / May 06 2016


NIMML uses innovation to tackle challenges in infectious, immune-mediated, and chronic inflammatory disease research. BTI was founded in 2008 by Dr. Josep Bassaganya-Riera as a result of the technology developed at VT’s Nutritional Immunology and Molecular Medicine Laboratory (NIMML).

Go to NIMML Website